Project Grant HT94252410731
Award Date
9/15/24
Completion Date
9/14/27
Dollars Obligated
$381K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
The University of Pittsburgh has been awarded a $540,800 Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on microparticle delivery of chemokine muteins guiding chemokine receptor engineered Treg for tolerance induction after vascular composite allograft transplant. The 3-year award, which runs from September 15, 2024 to September 14, 2027, will support innovative scientific studies aimed at developing novel...
This federal Project Grant award for $278,418.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research on the delivery of chemokine muteins (modified chemokine proteins) to guide engineered regulatory T cells (Tregs) for inducing immune tolerance after vascular composite allograft transplants. The research is being conducted by the Rector & Visitors Of The University Of Virginia, a leading academic institution with...
This $305,917 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of an off-the-shelf reparative T regulatory cell (Treg) immunotherapy to limit tissue damage and initiate effective repair and resolution after lung injuries. The University of Pittsburgh, a major research institution, is the prime awardee on this 2-year grant with a performance period from December 1, 2023 to November 30,...
This $299,999 Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by Wake Forest University Health Sciences (WFUHS) to develop microparticle delivery of chemokine muteins for guiding chemokine receptor engineered regulatory T cells (Tregs) to induce tolerance after vascular composite allograft transplants. The research project aims to advance therapeutic...
This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
The University of Pittsburgh was awarded a $1,572,933 federal Project Grant under the Military Medical Research and Development program (CFDA 12.420) by the Defense Health Agency. The grant, effective January 1, 2025 through December 31, 2028, supports advanced biomedical research aimed at "Targeting Lysosomal Pathways to Improve Host Immunity Post Coronaviral Infections." This research aligns with the program's objective to transform healthcare for military service members,...
The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
This $6,699,872.00 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the "MICROGLIAL BREAKTHROUGHS IN LONGEVITY, AGING, AND SENESCENCE AFTER TBI (MICROBLAST)" research initiative at the University of Pittsburgh. The 4-year award, starting on Sep 30, 2024, aims to conduct advanced biomedical research focused on transforming healthcare for military service members, veterans, and the broader public by...
The University of Pittsburgh was awarded a $499,999 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research to develop nontoxic immunosuppression therapies using Vitamin D3 analogues for vascularized composite allotransplantation (VCA). The grant period runs from September 1, 2024 to August 31, 2026. This research aims to transform healthcare for military service members,...